Preoperative Insulin Therapy As a Marker for Type 2 Diabetes Remission in Obese Patients After Bariatric Surgery
Overview
Authors
Affiliations
Background: Obesity not only increases the chances of developing diabetes-one of the top causes of death in the United States-but it also results in further medical complications.
Objective: To compare the 6-month and 1-year postoperative remission rates of type 2 diabetic (T2D) patients after bariatric surgery based on preoperative glycosylated hemoglobin (A1C) stratification and pharmacologic therapy: insulin-dependent diabetic (IDD) versus noninsulin-dependent diabetic (NIDD).
Setting: Academic hospital, United States.
Methods: We retrospectively analyzed a prospectively maintained database of 186 obese patients with a diagnosis T2D who had undergone either a sleeve gastrectomy or a Roux-en-Y gastric bypass surgery at our hospital.
Results: At 6 months (n = 180), patients who were stratified by preoperative A1C levels (<6.5; ≥6.5 to<8; ≥8) had 70.5%, 51.7%, and 30.0% remission rates (P<.001) and at 1 year (n = 118) patients had 72.0%, 54.0%, and 42.8% remission rates (P = .053), respectively. When patients were substratified by preoperative pharmacologic therapy, IDD and NIDD patients had different remission rates within the same A1C level. At 6-months follow-up within A1C ≥6.5 to<8 (IDD versus NIDD), the remission rate was 23.5% versus 64.1% (odds ratio [OR]: .173, confidence interval [CI]: .0471, .6308, P = .0079), and within A1C ≥8 the remission was 24.0% versus 37.5% (OR: .5263, CI: .2115, 1.3096, P = .1676), respectively. At 1-year follow-up within A1C ≥6.5 to<8, the remission rate was 30.0% versus 62.9% (OR: .2521, CI: .0529, 1.2019, P = .0838), and within A1C ≥8 the remission was 31.4% versus 61.9% (OR: .2821, CI: .0908, .8762, P = .0286), respectively. Furthermore, when IDD patients were compared between A1C ≥6.5 to<8 and A1C ≥8 the remission rates were nearly identical, and for NIDD patients A1C was not significantly associated with remission regardless of the level, except at 6 months.
Conclusion: While a difference was observed between overall A1C levels-the lower the A1C level, the higher the remission rate-IDD patients had lower remission rates than NIDD patients irrespective of A1C levels; further, IDD patients performed similarly across A1C levels.
Diabetes Care. 2024; 48(Supplement_1):S167-S180.
PMID: 39651976 PMC: 11635032. DOI: 10.2337/dc25-S008.
Diabetes Care. 2023; 47(Suppl 1):S145-S157.
PMID: 38078578 PMC: 10725806. DOI: 10.2337/dc24-S008.
ElSayed N, Aleppo G, Aroda V, Bannuru R, Brown F, Bruemmer D Diabetes Care. 2022; 46(Suppl 1):S128-S139.
PMID: 36507637 PMC: 9810466. DOI: 10.2337/dc23-S008.
Silveira E, Pereira de Souza Rosa L, Silva E Alves de Carvalho Santos A, de Souza Cardoso C, Noll M Int J Environ Res Public Health. 2020; 17(11).
PMID: 32498226 PMC: 7312992. DOI: 10.3390/ijerph17113930.
Madadi F, Jawad R, Mousati I, Plaeke P, Hubens G Obes Surg. 2019; 29(12):4066-4076.
PMID: 31655953 DOI: 10.1007/s11695-019-04199-3.